Retinitis Pigmentosa Treatment
Mar 31, 2026
Top 8 Breakthrough Gene Therapies for Retinitis Pigmentosa Treatment
Gene therapy is rapidly emerging as a transformative approach for retinitis pigmentosa treatment and other retinal degenerative disorders, with the eye providing an ideal environment for targeted interventions. Notably, the retina became the first tissue to receive a retinitis pigmentosa gene therapy FDA approval i...
Read More...
Oct 11, 2022
Merck’s Sotatercept Trial Result; PARP Rivals Closing in on AstraZeneca and Merck’s Lynparza; FDA Clears GSK’s Boostrix for Pertussis; Fast Track Designation to Nanoscope Therapeutics’s MCO-010; FDA Awards Fast Track Designation to Eftilagimod Alpha Plus Pembrolizumab; Solid Biosciences to Acquire AavantiBio
Merck’s Sotatercept Clears Phase III Trial Merck’s USD 11.5 billion acquisition of Acceleron last year was based on the promise of pulmonary arterial hypertension (PAH) candidate sotatercept, which has recently met the mark in a much-anticipated phase III trial. The STELLAR trial found that adding the activin re...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
